Altimmune To Report Results Of Obesity Treatment On Sept. 28

Published Sep 27 2021 at 9:02 PM GMT
  • (RTTNews) - Biopharmaceutical company Altimmune, Inc.
  • (ALT) on Monday announced that the company will report results from a Phase 1 clinical trial of ALT-801 in overweight and obese subjects.
  • The company said it will discuss the results in a pre-market press release, conference call and webcast on September 28 at 8:30 a m ET.



  • Published Sep 27, 2021 9:02 PM GMT